Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma
Published in: ESMO Open
Access to document
10.1016/j.esmoop.2024.102248
document
Background: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors. Methods: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using...
Y. M. Geurts, S. I.M. Neppelenbroek, B. M.P. Aleman, C. P.M. Janus, A. D.G. Krol, D. J. van Spronsen, W. J. Plattel, J. M. Roesink, K. M.S. Verschueren, J. M. Zijlstra, H. R. Koene, M. R. Nijziel, E. C. Schimmel, E. de Jongh, F. Ong, L. C.J. te Boome, R. S. van Rijn, L. H. Böhmer, B. D.P. Ta, H. P.J. VisserE. F.M. Posthuma, Y. M. Bilgin, K. Muller, D. van Kampen, C. So-Osman, J. S.P. Vermaat, R. J. de Weijer, M. J. Kersten, F. E. van Leeuwen, M. Schaapveld
Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials
Published in: Leukemia and Lymphoma
Access to document
10.1080/10428194.2024.2390565
document
Sára Rossetti, Sidsel J. Juul, Marleen A.E. van der Kaaij, Catherine Fortpied, Paul Meijnders, Berthe M.P. Aleman, John M.M. Raemaekers, Hanneke C. Kluin‑Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Wouter J. Plattel, Martin Hutchings, Maja V. Maraldo
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.23.01745
document
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of...
Massimo Federico, Catherine Fortpied, Yana Stepanishyna, Manuel Gotti, Richard Van Der Maazen, Caterina Cristinelli, Alessandro Re, Wouter Plattel, Julien Lazarovici, Francesco Merli, Lena Specht, Jean Marc Schiano De Colella, Martin Hutchings, Annibale Versari, Véronique Edeline, Aspasia Stamatoulas, Theodore Girinsky, Umberto Ricardi, Berthe Aleman, Bart MeulemansSanne Tonino, John Raemaekers, Marc André
Radiomics Based Subtype Discrimination in Classic Hodgkin Lymphoma Using 18-FDG PET/CT Imaging: A Proof-of-Concept Study
Background:In classic Hodgkin Lymphoma (cHL), the tumor microenvironment (TME) plays a crucial role in distinguishingamong the four histopathological subtypes. The TME comprises over 95% of the tumor mass and shows adistinctive cellular composition for each subtype. The accurate determination of subtypes in cHL throughbiopsies can be challenging, especially for needle biopsies. As novel therapies increasingly target disease-specific features, classifying the TME in cHL could emerge as a valuable source of information in the future. Theintegration of machine learning and radiomics, a quantitative method applied to medical imaging, holdspromise...
Roeland Vas Nunes, Minne Schalekamp, Christian Roest, Filipe Montes de Jesus, Gerwin Huls, Arjan Diepstra, Walter Noordzij, Wouter Plattel, Marcel Nijland
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
Published in: -
Access to document
10.1182/bloodadvances.2023010412
document
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is under-investigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (IG) and T-cell receptor (TR) rearrangements was performed in paired cHL diagnosis and recurrences of 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal IG rearrangements were detected by next-generation sequencing (NGS) in 69/120 (58%) diagnosis and recurrence samples. The clonal relationship could be established...
Diede Ag van Bladel, Wendy B C Stevens, Leonie I Kroeze, Ruben Al de Groen, Fleur A de Groot, Jessica Lm van der Last-Kempkes, Madeleine R Berendsen, Jos Rijntjes, Jeroen A C W Luijks, Irina Bonzheim, Ellen van der Spek, Wouter J Plattel, Johannes Pruijt, Susan Dpwm de Jonge-Peeters, Gerjo A Velders, Chantal Lensen, Esther R van Bladel, Birgit Federmann, Brigiet Hoevenaars, Agata PastorczakJutte van der Werff Ten Bosch, Joost S P Vermaat, Peet Nooijen, Konnie M Hebeda, Falko Fend, Arjan Diepstra, J Han Jm van Krieken, Patricia J T A Groenen, Michiel van den Brand, Blanca Scheijen